Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214461 | 0.99 | KAT2B (0.73) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL6218547 | 0.95 | KAT2B (0.74) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL112161 | 0.89 | KAT2B (0.70) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL29519350 | 0.89 | KAT2B (0.70) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL8246358 | 0.88 | KAT2B (0.58) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL27655316 | 0.87 | KAT2B (0.71) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL6216875 | 0.86 | KAT2B (0.77) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL17743370 | 0.85 | KAT2B (0.68) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL29519405 | 0.84 | KAT2B (0.73) | KAT2BMAPTLMNAPKMPRSS1 | |
| Hydrochloric Acid SCHEMBL514469 | 0.83 | KAT2B (1.00) | KAT2BMAPTLMNAPKMPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016073652-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | UNITHER VIROLOGY, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | KAT2B 3405/4885MAPT 4825/4885LMNA 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.